Source: Business Wire
JERUSALEM, Israel--(BUSINESS WIRE) via Individual Inc. -- January 29,
1997--Teva
Pharmaceutical Industries Ltd. (Nasdaq:TEVIY) today announced it has
received approval from the Food and Drug Administration to manufacture and
market Selegiline 5 mg. tablets.
Selegiline is a generic equivalent of Somerset's Eldepryl tablets, a drug
for the treatment of Parkinson's disease. Other generic versions of this
product have been introduced over the last several months.
Teva Pharmaceutical Industries Ltd., is Israel's largest pharmaceutical
company, with three quarters of its sales outside Israel, mainly in the
United States. The Company develops, manufactures and markets branded and
generic human pharmaceuticals, bulk pharmaceutical chemicals, medical
disposable and veterinary products.
CONTACT: Dan Suesskind | Chief Financial Officer | (011) 9722-5-892-840 |
or | Investor Relations: | Donna N. Stein | Press: Brian Maddox |
Morgen-Walke Associates, Inc. | (212) 850-5600 [01-29-97 at 09:08 EST,
Business Wire]
Contact: Business Wire
